Detailed Narrative
FY26 Performance and Strategic Product Shift
Accent Microcell reported a total sales volume of 15,000 metric tons for FY26, achieving a gross profit percentage of approximately 38%. The company's strategic focus on premium products, particularly SMCC and Spheres, significantly contributed to H2 FY26 performance. This shift is evident in the export revenue, which increased to 63% of total sales from 53% in the prior year, with 90% of MCC Spheres being exported in H2 FY26.
Unit 3 Expansion: Timelines and Revenue Potential
The crucial Unit 3 expansion project has experienced delays, with Phase 1, dedicated to premium excipients (CCS, CMC, SSD), now expected to commence commercial production by June 25th, 2026, following regulatory submissions. Phase 2, focusing on MCC, is projected to go live in March 2027. Management anticipates Unit 3 Phase 1 to generate a peak annual revenue of ₹150 crores, with an expected 50-60% utilization for 9 months in FY27, contributing roughly 40% of existing revenue from Units 1 and 2.
Product Strategy and Realization from New Capacities
Accent Microcell is targeting high-value products from Unit 3, including CCS with an expected realization of ₹650-700 per kg. The company is also pioneering pulp-based CMC production in India, with domestic selling prices of ₹400 per kg and export prices of ₹800-900 per kg. This strategic shift towards premium, higher-realization products is projected to increase blended profit margins by at least 2-3 percentage points going forward⏳.
Raw Material Sourcing and Cost Management
The company has effectively managed raw material costs, passing on nominal increases in wood pulp prices to customers. Accent Microcell sources its wood pulp from diverse international suppliers in the USA, Sweden, Canada, and Indonesia, avoiding reliance on China. Furthermore, a high export-to-import ratio (3x) allows the company to benefit from currency devaluation, mitigating the financial impact of raw material price fluctuations.
Working Capital and Funding Strategy
Accent Microcell aims to normalize its working capital and receivables, which have shown a stretch in FY26 (₹90 crores in receivables), by H1 or the end of FY27. The company maintains a debt-free status, having opted for a rights issue over debt for funding Unit 3 to gain competitive advantage. Future funding for Phase 1 and 2 will primarily come from internal accruals and the rights issue, with no new debt planned, supported by approximately ₹20 crores in cash.
Sales Channel Mix and Trading Volume Outlook
Currently, 85% of the company's sales are through distributors, with 15% from direct sales. Trading activities constituted 25-30% of total sales volume in FY26, amounting to ₹90 crores, and generated margins of 5-6%. Management expects a substantial decrease in trading volumes once the new manufacturing capacities from Unit 3 Phase 1 and 2 become operational, indicating a strategic shift towards higher-margin in-house production.